With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.122833-04-9,2-Methoxy-4-(4-methylpiperazin-1-yl)aniline,as a common compound, the synthetic route is as follows.
A solution of 2-chloro-9-cyclopentyl-7-ethyl-purin-8-one (Method 5) (0.1 g), 2-methoxy- 4-(4-methylpiperazin-l-yl)aniline (Compound 46-3, page 138 in WO 04/080980) (0.16 g) and 4-toluenesulphonic acid (0.13 g) in 2-propanol (2 mL) was heated at 1900C for Ih by microwave. After cooling the mixture was concentrated in vacuo and purified by FCC using 0-5% of (10:1 MeOetaxonc. aq. NH3) in DCM to afford the title compound (0.05 g, 31%) as a pale yellow foam; 1H NMR: (CDCl3) 1.34 (3H, t), 1.68 (2H, m), 2.33 (2H, m), 2.36 (3H, s), 2.60 (4H, m), 3.17 (4H, m), 3.87 (2H, q), 3.89 (3H, s), 4.81 (IH, tt), 6.55 (IH, dd), 6.57 (IH, s), 7.30 (IH, s), 7.86 (IH, s), 8.25 (IH, d); m/z: MH+ 453; EAA: 0.220; EAA2: 0.0538.
122833-04-9, The synthetic route of 122833-04-9 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2009/24824; (2009); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics